These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 31173724)
21. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Schrör K Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351 [TBL] [Abstract][Full Text] [Related]
22. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative. Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210 [TBL] [Abstract][Full Text] [Related]
23. NO-releasing zeolites and their antithrombotic properties. Wheatley PS; Butler AR; Crane MS; Fox S; Xiao B; Rossi AG; Megson IL; Morris RE J Am Chem Soc; 2006 Jan; 128(2):502-9. PubMed ID: 16402837 [TBL] [Abstract][Full Text] [Related]
24. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo. Pircher J; Fochler F; Czermak T; Mannell H; Kraemer BF; Wörnle M; Sparatore A; Del Soldato P; Pohl U; Krötz F Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2884-91. PubMed ID: 23023375 [TBL] [Abstract][Full Text] [Related]
26. Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents. Xie Y; Shao L; Wang Q; Bai Y; Chen Z; Li N; Xu Y; Li Y; Yang G; Bian X Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3731-3735. PubMed ID: 30343953 [TBL] [Abstract][Full Text] [Related]
28. Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. Apostoli GL; Solomon A; Smallwood MJ; Winyard PG; Emerson M J Thromb Haemost; 2014 Nov; 12(11):1880-9. PubMed ID: 25163536 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of arterial thrombosis and platelet function by nafazatrom. Buchanan MR; Blajchman M; Hirsh J Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186 [TBL] [Abstract][Full Text] [Related]
30. Antiplatelet and antithrombotic activities of NQ301, 2-chloro-3-(4-acetophenyl)-amino-1,4-naphthoquinone. Kang WS; Ryu CK; Chung KH; Ko MW; Joo JC; Yuk DY; Yoo HS; Yun YP Biol Pharm Bull; 1999 Dec; 22(12):1284-7. PubMed ID: 10746156 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Kalinowski L; Matys T; Chabielska E; Buczko W; Malinski T Hypertension; 2002 Oct; 40(4):521-7. PubMed ID: 12364357 [TBL] [Abstract][Full Text] [Related]
32. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Pawlak R; Chabielska E; Golatowski J; Azzadin A; Buczko W Thromb Haemost; 1998 Jun; 79(6):1208-12. PubMed ID: 9657449 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet aggregation by nitric oxide donors improves with rest. Broadley AJ; Schmitt M; Frenneaux MP Platelets; 2003 Sep; 14(6):347-9. PubMed ID: 14602547 [TBL] [Abstract][Full Text] [Related]
34. New targets for antithrombotic drugs. Thiagarajan P Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968 [TBL] [Abstract][Full Text] [Related]